Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Tacrolimus for renal preservation after liver transplant
NCT04258423Phase 3Terminated
- Sponsor
- Indiana University
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in kidney failure (ESRD) (2 arms), sponsored by Indiana University. Primary endpoints: Glomerular Filtration Rate at 36 months and Number of Patients Who Experience Transplant Rejection at 36 months. Started Dec 2019; status: terminated.
02
Drugs
everolimus
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT04258423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258423.